Fig 1: Zeb1 expression in placenta tissues. Immunohistochemical staining for the expression of (A) Zeb1 and (B) VEGF in placenta tissues (magnification, ×100 and ×400). **P<0.05 vs. PA tissues. E-cad, E-cadherin; N-cad, N-cadherin; PA, placenta accrete; TRAIL-R, TNF receptor superfamily member; UPA, placenta previa without PA; VEGF, vascular endothelial growth factor; Zeb1, zinc finger E-box-binding homeobox 1. Zeb1 expression in placenta tissues. Immunohistochemical staining for the expression of (C) E-cad in placenta tissues (magnification, ×100 and ×400). **P<0.05 vs. PA tissues. (D and E) Expression of Zeb1, E-cad, N-cad, VEGF, TRAIL-R2 and TRAIL-R3 in placenta tissues was detected by western blot analysis and reverse transcription-quantitative PCR **P<0.05 vs. PA tissues; ##P<0.05 vs. UPA tissues. E-cad, E-cadherin; N-cad, N-cadherin; PA, placenta accrete; TRAIL-R, TNF receptor superfamily member; UPA, placenta previa without PA; VEGF, vascular endothelial growth factor; Zeb1, zinc finger E-box-binding homeobox 1.
Fig 2: TTP inhibits DR4/5 expression in human colon cancer cells. (A) Levels of TTP, DR4, and DR5 expression in four human colon cancer cell lines were determined by quantitative real-time PCR (qRT-PCR). (B) MTS assay; viability of KM12C and HT29 cells with TRAIL treatment was higher than that of HCT116 and SW480 cells. KM12C cells with high TTP expression and low DR4/5 expression, and SW480 cells with low TTP expression and high DR4/5 expression were selected for further studies. (C) Expression of TTP and DR4/5 in TTP siRNA-treated or control siRNA (scRNA)-treated KM12C cells by qRT-PCR and Western blot analysis. (D) MTS assay; siTTP sensitizes KN12C to TRAIL. (E) FACS analysis. Late apoptosis and cell death in KM12C with siTTP increased significantly. ** p < 0.01; *** p < 0.001.
Fig 3: ARE3 within DR5 and all three AREs in DR4 mRNA 3′-UTR are essential for the inhibitory effect of TTP. Schematic representation of luciferase reporter constructs with (A) 2521-bp DR5 and (B) 1250-bp DR4 mRNA 3′-UTR used in this study. White circles represent wild-type pentameric motif AUUUA, and gray circles represent mutated (mut) motif AGCA. (A) Only fragments with 3rd ARE within the DR5 3′-UTR show TTP-mediated inhibition of DR5. (B) Each single mutant of DR4-ARE showed a similar TTP inhibitory effect. (C) A single mutant of 3rd ARE of DR5 was confirmed to prevent the TTP inhibitory effect. Fragments derived from 2521-bp DR5 and 1250-bp DR4 mRNA 3′-UTR were cloned downstream of the luciferase reporter gene in psiCHECK luciferase expression vector. Inhibition of luciferase reporter containing DR5 and DR4 3′-UTR by TTP overexpression. Mapping of sequence in DR5 and DR4 mRNA 3′-UTR required for TTP inhibition of luciferase activity. SW480 cells were co-transfected with 500 ng of psiCHECK luciferase reporter construct containing fragmented or full AREs in DR4/5 and pcDNA6/V5-TTP or empty vector pcDNA6/V5. TTP-induced inhibition of luciferase activity observed with each construct was compared to that obtained with empty vector pcDNA6/V5. Cells were harvested, and luciferase activity was normalized to firefly activity. Luciferase values obtained from cells transfected only with luciferase construct full AREs were set to 1. Results represent the mean ± SD of three independent experiments (* p < 0.05; *** p < 0.001). ORF, open reading frame; ns, not significant. (D) RNA EMSA; RNA EMSA was performed by mixing cytoplasmic extracts containing 4 µg of total protein from pcDNA6/V5-TTP-transfected SW480 cells with 20 fmol of biotinylated wild-type (wt) or mutant (mut) probe. Control antibody or anti-TTP was added to reaction mixtures. Binding reactions were then separated by electrophoresis on 5% polyacrylamide gel under nondenaturing conditions. TTP indicate the position of the TTP-containing band.
Fig 4: Ethanol-induced neurodegeneration in primary organotypic brain slice culture involves TRAIL. (A) Organotypic brain slice cultures (OBSCs) were treated with ethanol (100 mM) for 4 days. TRAIL was measured by ELISA 16 h into withdrawal prior to onset of neuronal cell death. Ethanol caused a 36% increase in TRAIL in slice tissue. n = 9 control, 3 ethanol slices. (B) OBSCs were treated with ethanol (100 mM) for 24–72 h. TRAIL-R1/DR4 and TRAIL R2/DR5 were measured by Western blot. Ethanol caused a 1.55-fold increase in TRAIL-R1 protein levels at 24 h and a 1.66-fold increase at 72 h (* p < 0.05). Ethanol caused a trend toward a 1.2-fold increase in TRAIL-R2 protein levels at 72 h (p = 0.09, n = 9 control and 3 ethanol). Images of blots at 72 h of EtOH treatment are shown. (C,D) The ability of ethanol pretreatment to enhance TRAIL neurotoxicity was assessed. OBSCs were treated with ethanol for 48 h, which was followed by addition of recombinant TRAIL (0.75 µg/mL) for 24 h. Neurodegeneration was assessed by propidium iodide (PI) uptake. (C) Ethanol and TRAIL alone caused a moderate amount of neurodegeneration. However, ethanol pretreatment caused a robust, synergistic enhancement in neurodegeneration due to TRAIL. ANOVA: F3.34 = 7.2, p = 0.0007. *** p < 0.001 vs. control, # p < 0.05 vs. TRAIL alone, Sidak’s multiple comparisons test. n = 9–10 slices/group (D) Representative image showing enhancement of TRAIL neurodegeneration by ethanol pretreatment. (E) The role of TRAIL in ethanol-induced neurodegeneration was assessed using the TRAIL monoclonal antibody (αTRAIL mAb). OBSC was treated with ethanol (100 mM) for 72 h followed by ethanol withdrawal (EW) for 24 h ± rat αTRAIL mAb (0.5 µg/mL) or rat immunoglobulin G (IgG) isotype control. EW caused significant neurodegeneration, which was completely abolished by αTRAIL mAb. ANOVA: F4.42 = 9.3, p < 0.0001. **** p < 0.0001 vs. IgG alone control, ††† p < 0.001 vs. EW + IgG, Sidak’s multiple comparisons test. n = 7–16 slices per group. (F) Representative images showing inhibition of EW-induced neurodegeneration by αTRAIL mAb. Fluorescent PI images were converted to black and white images for ease of visualization.
Fig 5: TTP destabilizes mRNA via interaction with ARE within DR4/5 mRNA 3′-UTR. (A) Expression of DR4 and DR5 mRNA in SW480/pcDNA and SW480/TTP cells was determined by quantitative real-time PCR at indicated times after adding 5 µg/mL actinomycin D. mRNA half-life was calculated by nonlinear regression of mRNA levels at indicated times after addition of actinomycin D. Results shown represent mean ± SD of three independent experiments (*** p < 0.001). (B) Analysis of full base pairs of DR4/5 3′-UTR. Schematic representation of luciferase reporter constructs used in this study. Oligonucleotides derived from full-bp DR4/5 mRNA 3′-UTR were cloned downstream of the luciferase reporter gene in psiCHECK luciferase expression vector. White circles represent wild-type pentameric motif AUUUA. (C) Inhibition of luciferase reporter containing DR4/5 mRNA 3′-UTR by TTP overexpression. SW480 cells were co-transfected with 500 ng of psiCHECK luciferase reporter construct containing full AREs in DR4/5 and pcDNA6/V5-TTP or empty vector pcDNA6/V5. After normalization, luciferase activity from SW480 cells transfected with psiCHECK vector alone was set to 1.0. Results represent the mean ± SD of three independent experiments (** p < 0.01; *** p < 0.001). ORF, open reading frame; ns, not significant.
Supplier Page from Abcam for Anti-DR5 antibody